Fundraising FoxLumabs
1 known investors
Find your way into Lumabs
Sign up to see every warm intro you have to Lumabs
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lumabs team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
LUMABS BV develops RAPPID, a rapid, one-step immunoassay technology that enables sensitive antibody detection from minimal blood samples for diagnostics and therapeutic monitoring. The company serves immunoassay diagnostic companies, clinical laboratories, biotech organizations, and research groups seeking faster, more sensitive alternatives to traditional ELISA-based assays.
Investors · 1
NLClisted by NLCAmsterdam
How we know: NLC's portfolio page · Not right? Tell us
Frequently asked questions
- What does Lumabs do?
- LUMABS BV develops RAPPID, a rapid, one-step immunoassay technology that enables sensitive antibody detection from minimal blood samples for diagnostics and therapeutic monitoring. The company serves immunoassay diagnostic companies, clinical laboratories, biotech organizations, and research groups seeking faster, more sensitive alternatives to traditional ELISA-based assays.
- Who are Lumabs's investors?
- Lumabs's investors include NLC.